Laurel Fitzhugh — Status: Draft, working document | Updated July 10, 2026
Laurel Fitzhugh presents with a decades-long multi-system clinical picture that has been managed as a collection of separate diagnoses. The central fact of the neurological picture is cumulative, ongoing damage to the central nervous system, expressed most consequentially as a loss of autonomic regulatory capacity. This damage has two converging sources: a developmentally established vulnerability present before any diagnosable disease, and a series of acquired insults accumulating across decades, including but not limited to two strokes. The strokes are contributing events within this longer history, not the origin or organizing center of the picture. Vascular and clotting mechanisms are one candidate pathway among the acquired insults and are treated here as a minor, unresolved question rather than the document’s central argument. The individual diagnoses across this clinical history are downstream expressions of a nervous system operating with progressively reduced regulatory reserve.
I. The Damage Itself
The current functional baseline reflects accumulated, ongoing CNS damage, not the residue of two past events. Proprioceptive function now requires increasing conscious effort and compensation for routine ambulation, with intermittent gait abnormality. The baseline has been permanently reduced by each contributing insult and continues to decline.
Structural findings, July 2025 MRI: apparent encephalomalacia in the right insula posteriorly, corresponding to the region of the 2018 infarct. Mild chronic microangiopathy appears slightly increased from the prior MRI of July 2018, confirming ongoing progression. No pathologic enhancement identified.
Autonomic regulation as the central deficit. The right insula is the primary CNS site of autonomic integration. Damage here, layered onto developmental vagal tone deficits documented in the SetPoint reference (early antibiotic exposure, ACE-related autonomic impairment, pernicious anemia demyelination, chronic inflammatory reflex fatigue), represents a cumulative reduction in the nervous system’s capacity to regulate systemic inflammation. This is the mechanism through which CNS damage has driven the severity and refractoriness of the broader autoimmune picture, not merely a consequence of it.
The insular damage also has HPA axis consequences. The right insula participates in HPA modulation through hypothalamic connections. A flattened diurnal cortisol rhythm, absent the classic RA morning stiffness pattern and now managed with physiologic low-dose hydrocortisone replacement, is consistent with CNS-origin HPA dysregulation as a contributing factor.
White matter disease as an independent, ongoing process, documented across four imaging time points spanning nine years:
- June 2016 — present at first stroke imaging, predating the acute event; few small scattered foci in deep and subcortical white matter
- July 2018 — bilateral at time of second stroke; mild, diffuse, in juxtacortical and deep white matter of both hemispheres; bilateral distribution independent of either stroke location
- May 2024 — more extensive, localized to posterior right frontal region adjacent to motor and autonomic pathways
- July 2025 — mild chronic microangiopathy, slightly increased from 2018 baseline
This process predates both strokes, was already bilateral at the time of the second stroke, and has continued progressing independent of either infarct location. It is background, ongoing disease, not stroke-related damage.
II. Two Converging Tracks
Developmental Track
Continuous secondhand smoke exposure from the prenatal period through age 17. Continuous antibiotic exposure from infancy through age 7 depleted the gut microbiome during the critical developmental window for autonomic nervous system maturation and mucosal immune tolerance, producing impaired vagal afferent signaling and reduced regulatory immune capacity. A high Adverse Childhood Experiences score produced measurable, persistent reductions in parasympathetic tone and heart rate variability during sensitive developmental periods, only partially reversible, establishing sympathetic dominance that compounds every later reduction in vagal anti-inflammatory capacity. This track was active before any autoimmune disease was identifiable.
Acquired Track
A chronological sequence of insults, each reducing CNS reserve further:
- Ages 17–30, significant alcohol use. Ceased at age 30.
- Age 17 to present, tobacco use. Current smoker.
- Pre-2008, pregabalin episodes. Prescribed for pain labeled fibromyalgia, predating the RA diagnosis by at least eight years. Produced sudden loss of postural tone without dizziness, warning, or loss of consciousness, consistent with pregabalin-induced negative myoclonus, a cortical inhibitory phenomenon exceeding standard adverse effects in character and severity. Resolved within days of discontinuation. This is the earliest documented evidence of a nervous system operating with reduced reserve.
- 2008, methotrexate reaction. Within three to four weeks of starting methotrexate following RA diagnosis, severe peripheral neuropathy developed alongside an unprecedented psychiatric presentation: continuous uncontrollable crying and suicidal ideation, beginning within days of the first dose. Both resolved rapidly and completely after discontinuation. The severity and character substantially exceeded typical low-dose methotrexate neuropsychiatric effects.
- 2008–2018, biologic failure pattern. Four biologics failed. Humira and Simponi produced no response of any kind. Tocilizumab and abatacept both produced neurological adverse effects requiring discontinuation. This binary pattern, complete non-response or amplified neurological reaction with no middle ground, recurs across mechanistically unrelated drug classes over more than a decade and reflects a constitutionally compromised nervous system rather than a series of unrelated drug sensitivities.
- 2016, first stroke. Left temporal lobe acute ischemic infarct, June 2016, preceded by a motor vehicle accident ten days prior. No cardioembolic source identified despite TEE with bubble study in 2017. Same-day MRI documented the first evidence of small vessel CNS disease, already present and described as chronic, not acute. Same-day MRA established baseline constitutional vascular architecture: diminutive vertebrobasilar system, ectatic right persistent trigeminal artery, a 4mm right cavernous ICA aneurysm, and a probable 2mm left MCA branch aneurysm, with no prior imaging for comparison.
- 2017, left hand signal. Neuropsychological evaluation documented moderate left hand motor impairment, flagged by the evaluator as inconsistent with the left temporal stroke location, suggesting right hemisphere dysfunction already developing before the second stroke. A separate one-day episode of memory disturbance and repetitive thinking between the two strokes, attributed at the time to statin side effects, warrants reconsideration as a possible minor vascular event given the bilateral small vessel disease already in progress.
- 2018, second stroke. Right insular cortical CVA in July 2018, extending into the adjacent frontal operculum, again with no embolic source identified. MRI documented small vessel disease now bilateral, independent of either stroke’s location, confirming a diffuse process rather than stroke-related damage. CTA documented the right ICA aneurysm grown to 6mm from the 4mm 2016 baseline.
- 2024 onward, systemic escalation. Following a significant dysbiosis event in late 2023, the clinical picture escalated across multiple systems simultaneously, including a marked acceleration of structural joint destruction and first appearance of a mast cell activation pattern. The dysbiosis event increased CNS toxic load through multiple channels: LPS crossing a blood-brain barrier more permeable than classical models assumed, inflammatory cytokines with direct CNS effects, disrupted gut-derived neuroactive compound production, and increased oxidative stress reaching CNS tissue directly. This was a direct neurological insult, not a parallel stressor.
- Hydroxychloroquine vestibular crisis, late 2025/early 2026. Acute vestibular damage of sufficient severity to prompt emergency services, with presentation indistinguishable from major stroke and inability to stand. Damage did not fully reverse. B12 requirement escalated permanently following this event.
Each insult in this track reduced the baseline further. None fully reversed. The current functional baseline reflects the accumulated total.
III. Vascular Findings
The vascular system shows constitutional abnormalities present from the earliest available imaging: trigeminal artery ectasia, a diminutive vertebrobasilar system, and two aneurysms, one of which grew substantially (4mm to approximately 1.2cm over seven years) before Pipeline embolization in May 2023, successful with no residual filling on follow-up imaging. The other has remained stable across nine years of surveillance. A third variant, a dorsal outpouching along the trigeminal artery, has since been characterized as a likely small coursing vessel rather than a true aneurysm.
A December 2022 antiphospholipid antibody panel returned two elevated values out of five tested (anticardiolipin IgM and beta-2 glycoprotein I IgM), with confirmatory testing never ordered and results never communicated to Barrow neurology. This remains an open, unconfirmed diagnostic question.
Whether this vascular picture reflects a hypercoagulable tendency contributing to the two strokes is unresolved and, based on day-to-day clotting behavior, considered unlikely as a primary mechanism. The more consistent explanation is that chronic systemic inflammation produced transient, localized endothelial vulnerability at the time of each stroke, rather than a standing clotting disorder. Routine clotting function outside these episodes has been normal. Pending JAK2 V617F and confirmatory antiphospholipid testing, deferred to Barrow, will help distinguish a primary clotting disorder from this inflammatory-endothelial explanation, but a hypercoagulable state should not be treated as established or as the leading explanation for the strokes. This question is secondary to the central subject of this document and does not require resolution to support the rest of the framework.
IV. Family and Genetic Context
Family pattern. The paternal line shows clustering of palmar erythema across multiple siblings, one with rheumatoid arthritis, one with an undiagnosed tic disorder. The maternal line includes sisters with celiac disease and RA, and a mother with multiple strokes and colon cancer, whose late-life falls involved a loss-of-postural-tone mechanism worth noting as a possible heritable signal, not a confirmed one. The paternal brothers grew up in continuous proximity to petrochemical refineries in East Texas; whether the paternal clustering reflects heritable genetic tendency, transgenerational epigenetic exposure effects, or both is not resolvable from available evidence. The clustering itself is the data point.
Genetic findings. A partial 23andMe dataset has been analyzed through Promethease, with a fresh analysis pending. Several variants of interest have been identified: STAT4 G/T heterozygosity, an HLA-region locus homozygous T/T, homozygous ITGB3 PlA2, homozygous SOD2 A/A, heterozygous GSTP1 A/G, homozygous MTHFR A1298C, and HLA-B27 carrier status. Each represents one of the possible allele combinations at that locus, with published population-level associations to autoimmune, vascular, mitochondrial, or detoxification pathway function. None of these variants were flagged by 23andMe or by Promethease as notable findings. They are recorded here as background genetic context consistent with the constitutional picture, not as evidence supporting any specific mechanism or conclusion in this document. They should not be read as a converging signal toward antiphospholipid syndrome or any other diagnosis. Family genetic data across three generations is available for future comparative analysis.
V. The Broader System
The CNS picture operates in conjunction with a gut-barrier-immune axis driving continuous LPS translocation and systemic inflammatory amplification, a severely dysbiotic microbiome in a locked attractor state, and a helminthic therapy protocol that partially restored immune regulation between 2020 and 2023 before losing efficacy following the 2024 dysbiosis event. These are developed in separate reference documents.
The neurological system is the upstream integrating point tying these tracks together. The vagal tone deficit documented in the SetPoint reference, a five-factor cumulative deficit spanning the lifespan, is both a consequence of the CNS damage described here and the mechanism through which that damage amplifies the broader systemic picture. CNS damage reduced the central autonomic regulatory capacity that would otherwise have modulated the inflammatory response driven by the gut-barrier-immune axis. The gut-barrier-immune dysfunction provides the continuous inflammatory drive; the cumulative CNS damage removed the primary brake on that drive. The individual diagnoses across this clinical history are the visible surface of a system operating without adequate regulatory capacity at multiple levels simultaneously.
Cross-References
Constitutional Systems Model — Full Series
I — Constitutional CNS: Cumulative Neurological Damage and Autonomic Regulatory Failure
https://dittany.com/case-study-csm-constitutional-cns/
IIa — Vagal Tone Deficit: Five-Factor Cumulative Model and Cholinergic Anti-Inflammatory Pathway
https://dittany.com/case-study-csm-vagal-tone-deficit/
IIb — Neurological Patterns: Chronological CNS History, Imaging Series, Diagnostic Questions
https://dittany.com/case-study-csm-neurological-patterns/
IIc — SetPoint VNS Responder Analysis: Mechanistic Case, Pharmacological Response Pattern, Genuine Uncertainties
https://dittany.com/case-study-csm-setpoint-vns-responder-analysis/
IIIa — Gut Foundational Reference: Intestinal Barrier Dysfunction, Microbiome Locked Attractor State, LPS Translocation
https://dittany.com/csm-gut/
IIIb — Helminthic Therapy: Mechanism, Clinical Response History, Current Status, Relationship to VNS
https://dittany.com/case-study-csm-helminthic-therapy/
IIIc — Iron-Triggered Dysbiosis: Iron Trigger Analysis, Locked Attractor State, Post-Collapse Deterioration
https://dittany.com/iron-biome-relationship/
IVa — Pharmacological Phenotype: Amplified Response Pattern, Sensitization Threshold, PRN Constraint, Reset Dynamic
https://dittany.com/case-study-csm-pharmacological-phenotype/
This document reflects mechanistic relationships and personal hypotheses based on documented history and current research. It is a thinking tool, not a clinical record. Updated July 10, 2026.